Company Overview
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Revenue has grown at a 241.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Dec 2025 Revenue of $70.85M (+23359.9% YoY); net profit $-342.60M.
- Trailing 12 Months Year-on-year growth — revenue +95.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 241.9%, profit CAGR -54.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 241.95% |
| 1 Year: | 95.80% |
Compounded Profit Growth
| 5 Years: | -54.60% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +11.32% |
| 6 Months: | -39.91% |
| 3 Months: | +28.92% |
| 1 Month: | +18.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 241.9% over 5 years.
CONS
- Earnings shrank at -54.6% CAGR over 5 years.
- Trading 43.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VRDN Viridian Therapeutics, Inc. R2K | 19.08 | -5.70 | $2.11B | 0.00% | -40.74% | -58.14% | 241.95% | -54.60% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.87M | 1.32M | 1.46M | 1.33M | 2.05M | 2.11M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.00K | 75.00K | 70.57M | 132.00K | 141.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 93.94M | 106.84M | 110.58M | 122.88M | 116.31M |
| Operating Income | -1.63M | -2.61M | -2.49M | -3.13M | -3.54M | -3.45M | -4.08M | - | -6.94M | -7.35M | -5.89M | - | -4.62M | -8.86M | -9.15M | - | -11.74M | -8.94M | -11.23M | - | -8.00M | -6.37M | -5.41M | -18.52M | -18.00M | -14.13M | -25.89M | -29.56M | -29.79M | -72.47M | -59.27M | -51.22M | -55.90M | -72.19M | -83.48M | -93.87M | -106.77M | -40.01M | -122.75M | -116.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -86.25M | -100.11M | -33.93M | -116.95M | -101.32M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 550.00K | 514.00K | 560.00K | 3.28M | 3.46M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -86.91M | -100.73M | -34.60M | -120.36M | -104.90M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.64M | -2.63M | -2.56M | -3.15M | -3.62M | -3.52M | -4.15M | -5.97M | -6.98M | -7.31M | -5.83M | -6.39M | -4.66M | -8.71M | -9.01M | -10.32M | -11.63M | -8.90M | -11.23M | -10.12M | -8.04M | -6.43M | -5.49M | -18.46M | -17.96M | -14.04M | -25.69M | -29.49M | -28.91M | -68.15M | -55.06M | -47.66M | -48.54M | -64.99M | -76.69M | -86.91M | -100.73M | -34.60M | -120.36M | -104.90M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.82 | -1.48 | -2.91 | -2.21 | -1.25 | -0.98 | -1.06 | -0.86 | -1.61 | -1.27 | -1.09 | -0.79 | -1.02 | -1.15 | -0.87 | -1.00 | -0.34 | -1.08 | -0.90 |
| R&D Expense | 105.00K | 100.00K | 194.00K | 253.00K | 3.47M | 3.35M | 2.96M | 3.91M | 4.12M | 5.49M | 5.02M | 5.00M | 6.41M | 8.38M | 7.40M | 8.23M | 8.75M | 8.60M | 9.03M | 8.42M | 6.10M | 3.84M | 3.11M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 6.48M | 5.71M | 3.48M | 4.00M | 8.39M | 4.46M | 1.05M | - | 1.77M | 314.00K | 302.00K | 70.85M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 136.08M | 254.76M | 299.34M | 434.24M |
| Operating Income | -197.00K | -6.87M | -11.19M | -16.99M | -26.53M | -33.08M | -41.98M | -110.38M | - | -134.30M | -254.45M | -299.04M | -363.39M |
| EBITDA | - | - | - | - | - | - | - | - | - | -129.13M | -235.88M | -267.21M | -337.19M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 486.00K | 1.33M | 2.20M | 4.95M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -129.87M | -237.73M | -269.95M | -342.60M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.16M | -7.89M | -11.33M | -17.27M | -26.51M | -32.70M | -41.87M | -110.72M | - | -129.87M | -237.73M | -269.95M | -342.60M |
| Diluted EPS | - | - | - | - | - | - | - | -31.13 | - | -4.05 | -5.31 | -3.07 | -3.32 |
| R&D Expense | 225.00K | 347.00K | 1.00M | 13.69M | 19.62M | 30.42M | 34.79M | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 3.67M | 8.09M | 12.90M | 24.76M | 52.48M | 66.15M | 30.26M | 131.25M | - | 435.09M | 490.42M | 742.40M | 899.42M |
| Current Assets | - | - | - | - | - | - | - | - | - | 431.17M | 486.48M | 738.46M | 894.23M |
| Cash & Equivalents | 209.00K | 5.12M | 21.23M | 22.10M | 47.44M | 32.61M | 26.80M | 127.60M | - | 155.58M | 102.83M | 99.59M | 212.38M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | 451.00K | 102.00K | 102.00K | 0 | - |
| Total Liabilities | - | - | - | 9.71M | 13.97M | 14.80M | 14.51M | 11.22M | - | 40.03M | 48.40M | 70.76M | 177.25M |
| Current Liabilities | 27.30M | 1.99M | 2.47M | 6.88M | 3.90M | 6.73M | 10.18M | 10.67M | - | 33.35M | 26.64M | 47.87M | 70.70M |
| Long Term Debt | - | - | - | - | 10.00M | 10.00M | 7.67M | - | - | 4.64M | 20.20M | 20.58M | 49.94M |
| Total Debt | - | - | - | - | - | - | - | - | - | 5.26M | 21.05M | 21.09M | 50.69M |
| Total Equity | -23.89M | 5.99M | -45.29M | -61.92M | 38.51M | 51.34M | 15.75M | 120.04M | - | 395.06M | 442.02M | 671.64M | 722.17M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 41.31M | 53.99M | 80.99M | 101.83M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.17M | -2.21M | -6.90M | -14.76M | -28.17M | -26.84M | -36.06M | -29.78M | - | -93.84M | -184.17M | -232.32M | -276.39M |
| Investing Cash Flow | 6.00K | -274.00K | -95.00K | -250.00K | 1.03M | -29.91M | 28.23M | -50.48M | - | -115.13M | -94.25M | -228.65M | -37.56M |
| Financing Cash Flow | 1.26M | 7.40M | 12.71M | 15.87M | 52.47M | 41.92M | 70.00K | 101.31M | - | 322.24M | 225.67M | 457.74M | 426.74M |
| Capital Expenditure | -5.00K | -266.00K | -123.00K | -250.00K | -246.00K | -445.00K | -84.00K | -42.00K | - | -797.00K | -898.00K | -511.00K | -495.00K |
| Free Cash Flow | -1.17M | -2.48M | -7.02M | -15.01M | -28.41M | -27.29M | -36.14M | -29.82M | - | -94.64M | -185.07M | -232.83M | -276.89M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 113.28M | -52.75M | -3.23M | 112.79M |
| Share Buybacks | - | - | - | 2.00K | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -3.6% | -105.9% | -196.1% | -488.6% | -662.8% | -394.5% | -941.0% | -10,512.4% | - | -7,579.2% | -81,035.0% | -99,018.2% | -512.9% |
| Net Margin % | -39.3% | -121.7% | -198.5% | -496.8% | -662.3% | -390.0% | -938.6% | -10,544.3% | - | -7,329.2% | -75,711.5% | -89,387.1% | -483.6% |
| ROE % | 9.0% | -131.7% | 25.0% | 27.9% | -68.8% | -63.7% | -265.8% | -92.2% | - | -32.9% | -53.8% | -40.2% | -47.4% |
| ROCE % | 0.8% | -112.6% | -107.2% | -95.0% | -54.6% | -55.7% | -209.0% | -91.5% | - | -33.4% | -54.9% | -43.1% | -43.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.92% | 15.38M | $296.67M |
| 2 | Blackrock Inc. | 7.60% | 7.83M | $151.07M |
| 3 | Bellevue Group AG | 6.53% | 6.73M | $129.75M |
| 4 | State Street Corporation | 4.53% | 4.67M | $90.14M |
| 5 | Vanguard Capital Management LLC | 4.04% | 4.17M | $80.39M |
| 6 | Fairmount Funds Management LLC | 3.80% | 3.91M | $75.51M |
| 7 | Venrock Adviser, LLC | 3.77% | 3.88M | $74.90M |
| 8 | Price (T.Rowe) Associates Inc | 3.11% | 3.21M | $61.84M |
| 9 | Paradigm Biocapital Advisors LP | 3.05% | 3.15M | $60.74M |
| 10 | Wellington Management Group, LLP | 2.99% | 3.08M | $59.39M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRDN
VRDN Stock Falls To 9-Month Lows – What’s The Amgen Connection? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOQUhMVTVIdGpKRW1SdGNGX0gwVGhLQ0RwOVJvTkJaLS1QZkc4b1lyLXlZTm9IbjFmaWtYelREaDFPdnVWdmJBeGRjVkh2QUtzb05QT2FoUDdWTmF4MEFJV25qdXJNQkdaWERFMlFHT0JWbmplbnZ6RndiR1FISjJUMVhWNUhQUWIxUnY3Zj…
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOdWpCTHlWZUJWa0RaMmp5Q2hlbUF0N29QSmRjX2lUN0dBWkFCYVZuNUNSUFhjVk9SNWJ1UWhzWHRESGVVQUlZMTQ2bk0yajhCUUhNNkI4amdrTXhLeUlmdlFDNmFvakxJQnBUcER3T2otQ3RfVllfSV9OTGNIeEVCQ25ONEhycjlL?oc=5"…
Viridian’s Lumvoa becomes the first FDA-approved TED treatment - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVVBUVWRFZnpuMFd2bktDWmJzdFZOYXFqc08zYk5XN3dHdUN3am8tVkhyTkV6N3d6UUV0blVlQjR4T2lrYl8zLW51dThlNzVIX0gyTmFsZVFTeTVVUTVTMWMwZko2QzlsY1NZdlAwTV9JVTJXNGM4Z2plMEJ1bXF5ZFhhQm5QZkpHZUNYdD…
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPR1M3SThzcllHZ0ZySVg3UFhDbVNfNk5zT2NqbWl1dnhGaHFFR0s1QktFdFlBSXYwXzNzbnZTV0s4ZFNmQVo4eVhMdW9ha0kxRnYyemZkZ0E5R1MxVWNLTzdldDU1TTUyem9ENXQ4RGhRLWJZeUY0QnZuNEVjdjR0emxtRHR4VE5XN2d3N2…
Price-Driven Insight from (VRDN) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNX3pEWnJuUWNJNlpaMWJDRWNFVXUzRl80QTNmY2xaaURnZFRXS013dzc2cDdGaTZ0VVQxbnNLSnp1T1hoRFZrSEFFSnJTdE1xRDI5eC1LZGNQcm1MblJvd18xeG01MUN1WmJ4R3BOTF95eWtoMGh5M3BlemhWbU5NYWQyX3J2MGNSM1U1eH…
Viridian Therapeutic stock rating reiterated at Outperform by William Blair - Investing.com
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNdUZkUnBTZ1Y3WnNIazJETDQ4dFFIalR5VW14dDUxSkhDYTdNdE9mQWVLUzVpQ0RtMXVZV25fVWFQZDI2M0lSS2REbHMtTks3dloxbDJadld0dlZvVkpMdDJiVzlPWWdrdzZEOEI4Y3lYZlYxTEFpR0pmYTBRVFVIR29QTUFMMl9MRGpBeX…
VRDN — Frequently Asked Questions
What is the current share price of Viridian Therapeutics, Inc. (VRDN)?
As of 2026-07-14 21:23 PDT, Viridian Therapeutics, Inc. (VRDN) trades at $19.08 on NasdaqCM. Its 52-week range is $13.30 to $33.78.
What is the market capitalisation of VRDN?
Viridian Therapeutics, Inc. (VRDN) has a market capitalisation of $2.11B on NasdaqCM.
What is the P/E ratio of VRDN?
VRDN trades at a trailing price-to-earnings (P/E) ratio of -5.70. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.92.
What is the return on equity (ROE) of VRDN?
VRDN has a return on equity (ROE) of -58.14%. Its return on capital employed (ROCE) is -40.74%.
Is VRDN a good stock to buy?
This page provides a data-driven analysis of Viridian Therapeutics, Inc. (VRDN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.